Wanting closeness again is not something to apologize for, at any age. If intimacy has changed since menopause, it helps to know that providers often think in terms of two distinct tools — and that they address different things.
This article is educational and is not medical advice. Whether any therapy is appropriate is a decision made with an independent licensed provider who knows your history.
Two different tools, two different jobs
When menopause shifts intimacy, two things are often happening at once, and they don't always travel together. One is physical comfort — the vaginal and urinary tissue itself. The other is the broader experience of menopause: hot flashes, sleep, mood, and how you feel in your own body.
Providers tend to map these onto two categories of hormone therapy:
- Localized (vaginal) estrogen — a low-dose estrogen placed directly in the vaginal area, designed to act mainly on local tissue.
- Systemic hormone therapy — estrogen (with progesterone or a progestogen if you still have a uterus) absorbed throughout the body, aimed at body-wide menopausal symptoms.
They are not competitors. They answer different questions.
Source: [1] Genitourinary Syndrome of Menopause (StatPearls) — National Library of Medicine, [2] The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society, [4] Menopause: Medicines to Help You — U.S. Food & Drug Administration
What localized vaginal estrogen is meant to address
After menopause, falling estrogen changes the vaginal and urinary tissues — thinner, drier, less elastic, sometimes with discomfort during intimacy and more urinary symptoms. The medical term for this cluster is the genitourinary syndrome of menopause (GSM) [1].
Low-dose vaginal estrogen is formulated to work primarily where it's placed. Because it's local and low-dose, systemic absorption is generally limited compared with body-wide therapy [2][3]. That's a meaningful distinction for many women weighing safety. The North American Menopause Society's position statement reviews low-dose vaginal estrogen specifically for genitourinary symptoms and discusses its local action [2].
Important nuance: localized estrogen is built for tissue comfort. It is not designed to treat hot flashes, sleep disruption, or other whole-body symptoms — those generally fall outside what a local product is meant to do.
What systemic hormone therapy is meant to address
Systemic therapy circulates through the body, so providers consider it when the picture is broader — vasomotor symptoms (hot flashes, night sweats) and related menopausal changes [4]. The FDA's consumer guidance on menopausal hormone therapy describes its recognized uses and the framework of using it thoughtfully and individually [4].
Systemic therapy also carries a more involved risk conversation. The Women's Health Initiative trials are the large studies most often cited when providers discuss benefits and risks of systemic estrogen and estrogen-plus-progestin, including how risk varies by age, time since menopause, and whether estrogen is taken alone or with a progestogen [5]. This is exactly the kind of individualized weighing a provider does — not a one-size-fits-all answer.
If you still have a uterus, systemic estrogen is generally paired with a progestogen to protect the uterine lining; that's a standard part of how providers structure systemic regimens [2][4].
Where desire fits — and where it doesn't fit neatly
Here's the honest part. Desire is rarely one wire you can reconnect. It's shaped by comfort (pain or dryness can quietly dampen interest), by sleep and mood, by stress, by relationship dynamics, and by hormones — often all at once [6]. The Endocrine Society and other bodies emphasize this multifactorial picture when discussing female sexual concerns [6].
So a thoughtful provider doesn't just hand you a single product. They try to sort out which threads are doing what:
- If discomfort is the main barrier, localized tissue support may be relevant.
- If hot flashes and disrupted sleep are eroding everything, the conversation may widen to systemic options.
- If the change is more about stress, life load, or relationship distance, hormones may be only part of a larger answer.
None of this requires you to have it figured out before you reach out. Sorting it out *is* the visit.
What a provider weighs
When an independent provider considers these tools, they're typically thinking about:
- Your symptom map — local comfort vs. whole-body symptoms, and which bothers you most.
- Your personal and family history — including blood clots, certain cancers, heart and vascular health, and liver health.
- Age and time since menopause — both influence the systemic risk conversation [5].
- Whether you have a uterus — which shapes whether a progestogen is added [2][4].
- Your goals and your comfort with risk — your priorities are part of the equation.
Labs and history don't "prescribe" anything. They give the provider context. A prescription is never guaranteed; it's a clinical decision made by the licensed provider.
Source: [5] Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials (JAMA), [6] Female Sexual Dysfunction: ACOG Practice Bulletin / Endocrine background — National Library of Medicine
Questions worth bringing to a first visit
You don't need the right vocabulary. But if it helps to walk in with notes, consider:
- *What's most likely driving my change — comfort, broader symptoms, stress, or a mix?*
- *Is my main issue local tissue comfort, or whole-body symptoms — and which tool fits which?*
- *Given my age and history, how do you think about the risks of systemic therapy versus localized estrogen?*
- *Are there non-hormonal options worth considering alongside, or instead?*
- *What would we monitor, and how would we know if something isn't right for me?*
And one more, said plainly: *wanting closeness again is a legitimate reason to be here.* It is.
A note on compounded options
You may encounter compounded hormone products in your reading. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether a compounded or an FDA-approved product is appropriate — if anything is — is a decision for an independent licensed provider.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. We don't provide care or guarantee any treatment. What we do is make the path simpler: we can help coordinate lab work, connect you with an independent licensed provider for a confidential visit, and — *if* that provider determines a therapy is appropriate and writes a prescription — coordinate fulfillment through an independent licensed pharmacy.
The medical decisions stay with your provider. The goal here is only to remove friction and embarrassment from a conversation that deserves to feel ordinary — because wanting comfort and closeness after menopause is exactly that.
*This article is educational and is not medical advice. Talk with a licensed provider about your individual situation.*
